nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—TYMS—prostate cancer	0.367	1	CbGaD
Pemetrexed—TYMS—Capecitabine—prostate cancer	0.234	1	CbGbCtD
Pemetrexed—GART—prostate gland—prostate cancer	0.00459	0.0675	CbGeAlD
Pemetrexed—GART—seminal vesicle—prostate cancer	0.00388	0.0571	CbGeAlD
Pemetrexed—SLC46A1—prostate gland—prostate cancer	0.00372	0.0548	CbGeAlD
Pemetrexed—SLC46A1—seminal vesicle—prostate cancer	0.00315	0.0463	CbGeAlD
Pemetrexed—GART—renal system—prostate cancer	0.00313	0.046	CbGeAlD
Pemetrexed—ATIC—prostate gland—prostate cancer	0.00312	0.0458	CbGeAlD
Pemetrexed—GART—urethra—prostate cancer	0.00307	0.0452	CbGeAlD
Pemetrexed—GART—bone marrow—prostate cancer	0.00236	0.0348	CbGeAlD
Pemetrexed—ATIC—epithelium—prostate cancer	0.00229	0.0337	CbGeAlD
Pemetrexed—ATIC—renal system—prostate cancer	0.00212	0.0312	CbGeAlD
Pemetrexed—TYMS—prostate gland—prostate cancer	0.00211	0.0311	CbGeAlD
Pemetrexed—DHFR—prostate gland—prostate cancer	0.00209	0.0308	CbGeAlD
Pemetrexed—GART—testis—prostate cancer	0.00202	0.0297	CbGeAlD
Pemetrexed—SLC29A1—prostate gland—prostate cancer	0.00189	0.0279	CbGeAlD
Pemetrexed—DCK—prostate gland—prostate cancer	0.00181	0.0266	CbGeAlD
Pemetrexed—DHFR—seminal vesicle—prostate cancer	0.00177	0.026	CbGeAlD
Pemetrexed—SLC46A1—testis—prostate cancer	0.00164	0.0241	CbGeAlD
Pemetrexed—DCK—seminal vesicle—prostate cancer	0.00153	0.0225	CbGeAlD
Pemetrexed—GART—lymph node—prostate cancer	0.00147	0.0215	CbGeAlD
Pemetrexed—DHFR—renal system—prostate cancer	0.00143	0.021	CbGeAlD
Pemetrexed—DHFR—urethra—prostate cancer	0.0014	0.0206	CbGeAlD
Pemetrexed—ATIC—testis—prostate cancer	0.00137	0.0202	CbGeAlD
Pemetrexed—SLC29A1—renal system—prostate cancer	0.00129	0.019	CbGeAlD
Pemetrexed—SLC29A1—urethra—prostate cancer	0.00127	0.0187	CbGeAlD
Pemetrexed—DCK—urethra—prostate cancer	0.00121	0.0178	CbGeAlD
Pemetrexed—SLC46A1—lymph node—prostate cancer	0.00119	0.0175	CbGeAlD
Pemetrexed—TYMS—bone marrow—prostate cancer	0.00109	0.016	CbGeAlD
Pemetrexed—DHFR—bone marrow—prostate cancer	0.00108	0.0159	CbGeAlD
Pemetrexed—ATIC—lymph node—prostate cancer	0.000995	0.0146	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—prostate cancer	0.000977	0.0144	CbGeAlD
Pemetrexed—DCK—bone marrow—prostate cancer	0.000933	0.0137	CbGeAlD
Pemetrexed—TYMS—testis—prostate cancer	0.000931	0.0137	CbGeAlD
Pemetrexed—Raltitrexed—TYMS—prostate cancer	0.000926	0.203	CrCbGaD
Pemetrexed—DHFR—testis—prostate cancer	0.000922	0.0135	CbGeAlD
Pemetrexed—SLC29A1—testis—prostate cancer	0.000835	0.0123	CbGeAlD
Pemetrexed—TYMS—Docetaxel—Cabazitaxel—prostate cancer	0.000816	0.193	CbGdCrCtD
Pemetrexed—DCK—testis—prostate cancer	0.000797	0.0117	CbGeAlD
Pemetrexed—Methotrexate—AOX1—prostate cancer	0.000738	0.162	CrCbGaD
Pemetrexed—Pralatrexate—TYMS—prostate cancer	0.000702	0.154	CrCbGaD
Pemetrexed—Leucovorin—TYMS—prostate cancer	0.000702	0.154	CrCbGaD
Pemetrexed—TYMS—lymph node—prostate cancer	0.000675	0.00992	CbGeAlD
Pemetrexed—DHFR—lymph node—prostate cancer	0.000668	0.00982	CbGeAlD
Pemetrexed—SLC29A1—lymph node—prostate cancer	0.000605	0.0089	CbGeAlD
Pemetrexed—DCK—lymph node—prostate cancer	0.000578	0.0085	CbGeAlD
Pemetrexed—TYMS—Paclitaxel—Cabazitaxel—prostate cancer	0.000563	0.133	CbGdCrCtD
Pemetrexed—Folic Acid—MTHFR—prostate cancer	0.00036	0.0789	CrCbGaD
Pemetrexed—Tetrahydrofolic acid—MTHFR—prostate cancer	0.00036	0.0789	CrCbGaD
Pemetrexed—Methotrexate—TYMS—prostate cancer	0.000309	0.0678	CrCbGaD
Pemetrexed—DCK—Estradiol valerate/Dienogest—Estrone—prostate cancer	0.00028	0.0662	CbGdCrCtD
Pemetrexed—ATIC—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.000267	0.063	CbGdCrCtD
Pemetrexed—Methotrexate—MTHFR—prostate cancer	0.000246	0.054	CrCbGaD
Pemetrexed—TYMS—Paclitaxel—Docetaxel—prostate cancer	0.000234	0.0552	CbGdCrCtD
Pemetrexed—DCK—Fulvestrant—Estradiol—prostate cancer	0.000227	0.0535	CbGdCrCtD
Pemetrexed—Folic Acid—CYP2E1—prostate cancer	0.000219	0.0479	CrCbGaD
Pemetrexed—DCK—Estradiol valerate/Dienogest—Estradiol—prostate cancer	0.000212	0.0501	CbGdCrCtD
Pemetrexed—DCK—Estradiol valerate/Dienogest—Ethinyl Estradiol—prostate cancer	0.000207	0.0489	CbGdCrCtD
Pemetrexed—DCK—Levorphanol—Estrone—prostate cancer	0.000198	0.0467	CbGdCrCtD
Pemetrexed—TYMS—Podofilox—Etoposide—prostate cancer	0.00015	0.0355	CbGdCrCtD
Pemetrexed—DCK—Levorphanol—Estradiol—prostate cancer	0.00015	0.0354	CbGdCrCtD
Pemetrexed—TYMS—Levorphanol—Estrone—prostate cancer	0.000149	0.0351	CbGdCrCtD
Pemetrexed—TYMS—Levorphanol—Estradiol—prostate cancer	0.000113	0.0266	CbGdCrCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—prostate cancer	0.000104	0.0246	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—prostate cancer	9.63e-05	0.0227	CbGdCrCtD
Pemetrexed—TYMS—Danazol—Ethinyl Estradiol—prostate cancer	7.45e-05	0.0176	CbGdCrCtD
Pemetrexed—DCK—Levonorgestrel—Ethinyl Estradiol—prostate cancer	7.09e-05	0.0167	CbGdCrCtD
Pemetrexed—Diarrhoea—Estradiol—prostate cancer	6.22e-05	0.000322	CcSEcCtD
Pemetrexed—Leukopenia—Capecitabine—prostate cancer	6.21e-05	0.000322	CcSEcCtD
Pemetrexed—Hypertension—Docetaxel—prostate cancer	6.19e-05	0.000321	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—prostate cancer	6.19e-05	0.000321	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—prostate cancer	6.19e-05	0.000321	CcSEcCtD
Pemetrexed—Malnutrition—Prednisone—prostate cancer	6.18e-05	0.000321	CcSEcCtD
Pemetrexed—Erythema—Prednisone—prostate cancer	6.18e-05	0.000321	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—prostate cancer	6.14e-05	0.000318	CcSEcCtD
Pemetrexed—Decreased appetite—Etoposide—prostate cancer	6.12e-05	0.000318	CcSEcCtD
Pemetrexed—Arthralgia—Docetaxel—prostate cancer	6.1e-05	0.000317	CcSEcCtD
Pemetrexed—Chest pain—Docetaxel—prostate cancer	6.1e-05	0.000317	CcSEcCtD
Pemetrexed—Myalgia—Docetaxel—prostate cancer	6.1e-05	0.000317	CcSEcCtD
Pemetrexed—Loss of consciousness—Capecitabine—prostate cancer	6.1e-05	0.000317	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—prostate cancer	6.1e-05	0.000316	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—prostate cancer	6.08e-05	0.000316	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Etoposide—prostate cancer	6.08e-05	0.000315	CcSEcCtD
Pemetrexed—Asthenia—Mitoxantrone—prostate cancer	6.07e-05	0.000315	CcSEcCtD
Pemetrexed—Fatigue—Etoposide—prostate cancer	6.07e-05	0.000315	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—prostate cancer	6.07e-05	0.000315	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	6.06e-05	0.000315	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—prostate cancer	6.03e-05	0.000313	CcSEcCtD
Pemetrexed—Constipation—Etoposide—prostate cancer	6.02e-05	0.000312	CcSEcCtD
Pemetrexed—Pain—Etoposide—prostate cancer	6.02e-05	0.000312	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—prostate cancer	6.02e-05	0.000312	CcSEcCtD
Pemetrexed—Dizziness—Estradiol—prostate cancer	6.01e-05	0.000312	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—prostate cancer	6.01e-05	0.000312	CcSEcCtD
Pemetrexed—Hypertension—Capecitabine—prostate cancer	5.99e-05	0.000311	CcSEcCtD
Pemetrexed—Myalgia—Capecitabine—prostate cancer	5.91e-05	0.000307	CcSEcCtD
Pemetrexed—Chest pain—Capecitabine—prostate cancer	5.91e-05	0.000307	CcSEcCtD
Pemetrexed—Arthralgia—Capecitabine—prostate cancer	5.91e-05	0.000307	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.87e-05	0.000305	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Epirubicin—prostate cancer	5.85e-05	0.000304	CcSEcCtD
Pemetrexed—Anaphylactic shock—Docetaxel—prostate cancer	5.85e-05	0.000304	CcSEcCtD
Pemetrexed—Oedema—Docetaxel—prostate cancer	5.85e-05	0.000304	CcSEcCtD
Pemetrexed—Infection—Docetaxel—prostate cancer	5.81e-05	0.000302	CcSEcCtD
Pemetrexed—Diarrhoea—Mitoxantrone—prostate cancer	5.79e-05	0.0003	CcSEcCtD
Pemetrexed—Vomiting—Estradiol—prostate cancer	5.78e-05	0.0003	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—prostate cancer	5.78e-05	0.0003	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Etoposide—prostate cancer	5.76e-05	0.000299	CcSEcCtD
Pemetrexed—Shock—Docetaxel—prostate cancer	5.76e-05	0.000299	CcSEcCtD
Pemetrexed—Nervous system disorder—Docetaxel—prostate cancer	5.74e-05	0.000298	CcSEcCtD
Pemetrexed—Thrombocytopenia—Docetaxel—prostate cancer	5.73e-05	0.000297	CcSEcCtD
Pemetrexed—Rash—Estradiol—prostate cancer	5.73e-05	0.000297	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—prostate cancer	5.73e-05	0.000297	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—prostate cancer	5.73e-05	0.000297	CcSEcCtD
Pemetrexed—Dermatitis—Estradiol—prostate cancer	5.72e-05	0.000297	CcSEcCtD
Pemetrexed—Anaemia—Prednisone—prostate cancer	5.72e-05	0.000297	CcSEcCtD
Pemetrexed—Skin disorder—Docetaxel—prostate cancer	5.68e-05	0.000295	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	5.68e-05	0.000295	CcSEcCtD
Pemetrexed—Oedema—Capecitabine—prostate cancer	5.67e-05	0.000294	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—prostate cancer	5.63e-05	0.000292	CcSEcCtD
Pemetrexed—Infection—Capecitabine—prostate cancer	5.63e-05	0.000292	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—prostate cancer	5.61e-05	0.000291	CcSEcCtD
Pemetrexed—Urticaria—Etoposide—prostate cancer	5.59e-05	0.00029	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—prostate cancer	5.58e-05	0.00029	CcSEcCtD
Pemetrexed—Anorexia—Docetaxel—prostate cancer	5.58e-05	0.000289	CcSEcCtD
Pemetrexed—Shock—Capecitabine—prostate cancer	5.57e-05	0.000289	CcSEcCtD
Pemetrexed—Abdominal pain—Etoposide—prostate cancer	5.57e-05	0.000289	CcSEcCtD
Pemetrexed—Body temperature increased—Etoposide—prostate cancer	5.57e-05	0.000289	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—prostate cancer	5.57e-05	0.000289	CcSEcCtD
Pemetrexed—Nervous system disorder—Capecitabine—prostate cancer	5.56e-05	0.000288	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—prostate cancer	5.56e-05	0.000288	CcSEcCtD
Pemetrexed—Thrombocytopenia—Capecitabine—prostate cancer	5.55e-05	0.000288	CcSEcCtD
Pemetrexed—Syncope—Prednisone—prostate cancer	5.55e-05	0.000288	CcSEcCtD
Pemetrexed—Pharyngitis—Epirubicin—prostate cancer	5.51e-05	0.000286	CcSEcCtD
Pemetrexed—Skin disorder—Capecitabine—prostate cancer	5.5e-05	0.000286	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—prostate cancer	5.49e-05	0.000285	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—prostate cancer	5.45e-05	0.000283	CcSEcCtD
Pemetrexed—Loss of consciousness—Prednisone—prostate cancer	5.44e-05	0.000282	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—prostate cancer	5.42e-05	0.000281	CcSEcCtD
Pemetrexed—Anorexia—Capecitabine—prostate cancer	5.4e-05	0.00028	CcSEcCtD
Pemetrexed—Nausea—Estradiol—prostate cancer	5.4e-05	0.00028	CcSEcCtD
Pemetrexed—Vomiting—Mitoxantrone—prostate cancer	5.38e-05	0.000279	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—prostate cancer	5.34e-05	0.000277	CcSEcCtD
Pemetrexed—TYMS—Levonorgestrel—Ethinyl Estradiol—prostate cancer	5.34e-05	0.0126	CbGdCrCtD
Pemetrexed—Hypertension—Prednisone—prostate cancer	5.34e-05	0.000277	CcSEcCtD
Pemetrexed—Rash—Mitoxantrone—prostate cancer	5.34e-05	0.000277	CcSEcCtD
Pemetrexed—Dermatitis—Mitoxantrone—prostate cancer	5.33e-05	0.000277	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Docetaxel—prostate cancer	5.33e-05	0.000277	CcSEcCtD
Pemetrexed—Myalgia—Prednisone—prostate cancer	5.26e-05	0.000273	CcSEcCtD
Pemetrexed—Arthralgia—Prednisone—prostate cancer	5.26e-05	0.000273	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—prostate cancer	5.25e-05	0.000273	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.23e-05	0.000271	CcSEcCtD
Pemetrexed—Dyspnoea—Docetaxel—prostate cancer	5.22e-05	0.000271	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—prostate cancer	5.19e-05	0.000269	CcSEcCtD
Pemetrexed—Hypersensitivity—Etoposide—prostate cancer	5.19e-05	0.000269	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.16e-05	0.000268	CcSEcCtD
Pemetrexed—Dyspepsia—Docetaxel—prostate cancer	5.15e-05	0.000267	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—prostate cancer	5.14e-05	0.000267	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—prostate cancer	5.1e-05	0.000265	CcSEcCtD
Pemetrexed—Decreased appetite—Docetaxel—prostate cancer	5.09e-05	0.000264	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—prostate cancer	5.08e-05	0.000263	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Docetaxel—prostate cancer	5.05e-05	0.000262	CcSEcCtD
Pemetrexed—Asthenia—Etoposide—prostate cancer	5.05e-05	0.000262	CcSEcCtD
Pemetrexed—Dyspnoea—Capecitabine—prostate cancer	5.05e-05	0.000262	CcSEcCtD
Pemetrexed—Oedema—Prednisone—prostate cancer	5.05e-05	0.000262	CcSEcCtD
Pemetrexed—Anaphylactic shock—Prednisone—prostate cancer	5.05e-05	0.000262	CcSEcCtD
Pemetrexed—Fatigue—Docetaxel—prostate cancer	5.05e-05	0.000262	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—prostate cancer	5.04e-05	0.000261	CcSEcCtD
Pemetrexed—Nausea—Mitoxantrone—prostate cancer	5.03e-05	0.000261	CcSEcCtD
Pemetrexed—Infection—Prednisone—prostate cancer	5.01e-05	0.00026	CcSEcCtD
Pemetrexed—Pain—Docetaxel—prostate cancer	5e-05	0.00026	CcSEcCtD
Pemetrexed—Constipation—Docetaxel—prostate cancer	5e-05	0.00026	CcSEcCtD
Pemetrexed—Dyspepsia—Capecitabine—prostate cancer	4.99e-05	0.000259	CcSEcCtD
Pemetrexed—Pruritus—Etoposide—prostate cancer	4.98e-05	0.000258	CcSEcCtD
Pemetrexed—Shock—Prednisone—prostate cancer	4.97e-05	0.000258	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—prostate cancer	4.96e-05	0.000257	CcSEcCtD
Pemetrexed—Nervous system disorder—Prednisone—prostate cancer	4.95e-05	0.000257	CcSEcCtD
Pemetrexed—Decreased appetite—Capecitabine—prostate cancer	4.93e-05	0.000256	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—prostate cancer	4.91e-05	0.000255	CcSEcCtD
Pemetrexed—Skin disorder—Prednisone—prostate cancer	4.9e-05	0.000254	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Capecitabine—prostate cancer	4.89e-05	0.000254	CcSEcCtD
Pemetrexed—Fatigue—Capecitabine—prostate cancer	4.88e-05	0.000253	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—prostate cancer	4.86e-05	0.000252	CcSEcCtD
Pemetrexed—Constipation—Capecitabine—prostate cancer	4.85e-05	0.000251	CcSEcCtD
Pemetrexed—Pain—Capecitabine—prostate cancer	4.85e-05	0.000251	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—prostate cancer	4.84e-05	0.000251	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—prostate cancer	4.84e-05	0.000251	CcSEcCtD
Pemetrexed—Diarrhoea—Etoposide—prostate cancer	4.82e-05	0.00025	CcSEcCtD
Pemetrexed—Anorexia—Prednisone—prostate cancer	4.81e-05	0.00025	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—prostate cancer	4.8e-05	0.000249	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Docetaxel—prostate cancer	4.79e-05	0.000248	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—prostate cancer	4.74e-05	0.000246	CcSEcCtD
Pemetrexed—Dizziness—Etoposide—prostate cancer	4.66e-05	0.000242	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Capecitabine—prostate cancer	4.63e-05	0.00024	CcSEcCtD
Pemetrexed—Abdominal pain—Docetaxel—prostate cancer	4.63e-05	0.00024	CcSEcCtD
Pemetrexed—Body temperature increased—Docetaxel—prostate cancer	4.63e-05	0.00024	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Prednisone—prostate cancer	4.6e-05	0.000239	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—prostate cancer	4.59e-05	0.000238	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—prostate cancer	4.54e-05	0.000236	CcSEcCtD
Pemetrexed—Urticaria—Capecitabine—prostate cancer	4.5e-05	0.000234	CcSEcCtD
Pemetrexed—Body temperature increased—Capecitabine—prostate cancer	4.48e-05	0.000232	CcSEcCtD
Pemetrexed—Abdominal pain—Capecitabine—prostate cancer	4.48e-05	0.000232	CcSEcCtD
Pemetrexed—Vomiting—Etoposide—prostate cancer	4.48e-05	0.000232	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—prostate cancer	4.47e-05	0.000232	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—prostate cancer	4.47e-05	0.000232	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—prostate cancer	4.47e-05	0.000232	CcSEcCtD
Pemetrexed—Dyspepsia—Prednisone—prostate cancer	4.44e-05	0.00023	CcSEcCtD
Pemetrexed—Rash—Etoposide—prostate cancer	4.44e-05	0.00023	CcSEcCtD
Pemetrexed—Dermatitis—Etoposide—prostate cancer	4.44e-05	0.00023	CcSEcCtD
Pemetrexed—Decreased appetite—Prednisone—prostate cancer	4.39e-05	0.000228	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—prostate cancer	4.38e-05	0.000227	CcSEcCtD
Pemetrexed—Fatigue—Prednisone—prostate cancer	4.35e-05	0.000226	CcSEcCtD
Pemetrexed—Syncope—Epirubicin—prostate cancer	4.34e-05	0.000225	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—prostate cancer	4.33e-05	0.000225	CcSEcCtD
Pemetrexed—Constipation—Prednisone—prostate cancer	4.32e-05	0.000224	CcSEcCtD
Pemetrexed—Hypersensitivity—Docetaxel—prostate cancer	4.31e-05	0.000224	CcSEcCtD
Pemetrexed—DCK—Desoximetasone—Prednisone—prostate cancer	4.26e-05	0.0101	CbGdCrCtD
Pemetrexed—Loss of consciousness—Epirubicin—prostate cancer	4.25e-05	0.000221	CcSEcCtD
Pemetrexed—Asthenia—Docetaxel—prostate cancer	4.2e-05	0.000218	CcSEcCtD
Pemetrexed—Nausea—Etoposide—prostate cancer	4.18e-05	0.000217	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—prostate cancer	4.18e-05	0.000217	CcSEcCtD
Pemetrexed—Hypersensitivity—Capecitabine—prostate cancer	4.17e-05	0.000217	CcSEcCtD
Pemetrexed—Pruritus—Docetaxel—prostate cancer	4.14e-05	0.000215	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—prostate cancer	4.14e-05	0.000215	CcSEcCtD
Pemetrexed—DCK—Diflorasone—Prednisone—prostate cancer	4.14e-05	0.00976	CbGdCrCtD
Pemetrexed—Gastrointestinal pain—Prednisone—prostate cancer	4.13e-05	0.000214	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—prostate cancer	4.12e-05	0.000214	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—prostate cancer	4.12e-05	0.000214	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—prostate cancer	4.12e-05	0.000214	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.09e-05	0.000212	CcSEcCtD
Pemetrexed—Asthenia—Capecitabine—prostate cancer	4.07e-05	0.000211	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—prostate cancer	4.01e-05	0.000208	CcSEcCtD
Pemetrexed—Urticaria—Prednisone—prostate cancer	4.01e-05	0.000208	CcSEcCtD
Pemetrexed—Pruritus—Capecitabine—prostate cancer	4.01e-05	0.000208	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—prostate cancer	4.01e-05	0.000208	CcSEcCtD
Pemetrexed—Diarrhoea—Docetaxel—prostate cancer	4e-05	0.000208	CcSEcCtD
Pemetrexed—Abdominal pain—Prednisone—prostate cancer	3.99e-05	0.000207	CcSEcCtD
Pemetrexed—Body temperature increased—Prednisone—prostate cancer	3.99e-05	0.000207	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—prostate cancer	3.95e-05	0.000205	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—prostate cancer	3.95e-05	0.000205	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—prostate cancer	3.93e-05	0.000204	CcSEcCtD
Pemetrexed—Infection—Epirubicin—prostate cancer	3.92e-05	0.000203	CcSEcCtD
Pemetrexed—Shock—Epirubicin—prostate cancer	3.88e-05	0.000201	CcSEcCtD
Pemetrexed—Diarrhoea—Capecitabine—prostate cancer	3.88e-05	0.000201	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—prostate cancer	3.87e-05	0.000201	CcSEcCtD
Pemetrexed—Dizziness—Docetaxel—prostate cancer	3.87e-05	0.000201	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—prostate cancer	3.86e-05	0.0002	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—prostate cancer	3.86e-05	0.0002	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—prostate cancer	3.83e-05	0.000199	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—prostate cancer	3.81e-05	0.000198	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—prostate cancer	3.81e-05	0.000198	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—prostate cancer	3.81e-05	0.000198	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.78e-05	0.000196	CcSEcCtD
Pemetrexed—Anorexia—Epirubicin—prostate cancer	3.76e-05	0.000195	CcSEcCtD
Pemetrexed—Dizziness—Capecitabine—prostate cancer	3.75e-05	0.000194	CcSEcCtD
Pemetrexed—Vomiting—Docetaxel—prostate cancer	3.72e-05	0.000193	CcSEcCtD
Pemetrexed—Hypersensitivity—Prednisone—prostate cancer	3.72e-05	0.000193	CcSEcCtD
Pemetrexed—Rash—Docetaxel—prostate cancer	3.69e-05	0.000191	CcSEcCtD
Pemetrexed—Dermatitis—Docetaxel—prostate cancer	3.69e-05	0.000191	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—prostate cancer	3.65e-05	0.000189	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—prostate cancer	3.65e-05	0.000189	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—prostate cancer	3.63e-05	0.000188	CcSEcCtD
Pemetrexed—Asthenia—Prednisone—prostate cancer	3.62e-05	0.000188	CcSEcCtD
Pemetrexed—Vomiting—Capecitabine—prostate cancer	3.6e-05	0.000187	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.6e-05	0.000187	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—prostate cancer	3.59e-05	0.000186	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—prostate cancer	3.58e-05	0.000186	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—prostate cancer	3.58e-05	0.000186	CcSEcCtD
Pemetrexed—Rash—Capecitabine—prostate cancer	3.57e-05	0.000185	CcSEcCtD
Pemetrexed—Pruritus—Prednisone—prostate cancer	3.57e-05	0.000185	CcSEcCtD
Pemetrexed—Dermatitis—Capecitabine—prostate cancer	3.57e-05	0.000185	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—prostate cancer	3.55e-05	0.000184	CcSEcCtD
Pemetrexed—Dyspnoea—Epirubicin—prostate cancer	3.52e-05	0.000183	CcSEcCtD
Pemetrexed—Anorexia—Doxorubicin—prostate cancer	3.48e-05	0.000181	CcSEcCtD
Pemetrexed—Nausea—Docetaxel—prostate cancer	3.48e-05	0.00018	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—prostate cancer	3.47e-05	0.00018	CcSEcCtD
Pemetrexed—TYMS—Clobetasol propionate—Prednisone—prostate cancer	3.46e-05	0.00816	CbGdCrCtD
Pemetrexed—Diarrhoea—Prednisone—prostate cancer	3.45e-05	0.000179	CcSEcCtD
Pemetrexed—Decreased appetite—Epirubicin—prostate cancer	3.43e-05	0.000178	CcSEcCtD
Pemetrexed—TYMS—Flunisolide—Prednisone—prostate cancer	3.41e-05	0.00806	CbGdCrCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—prostate cancer	3.41e-05	0.000177	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—prostate cancer	3.4e-05	0.000177	CcSEcCtD
Pemetrexed—TYMS—Triamcinolone—Prednisone—prostate cancer	3.38e-05	0.00798	CbGdCrCtD
Pemetrexed—Constipation—Epirubicin—prostate cancer	3.38e-05	0.000175	CcSEcCtD
Pemetrexed—Pain—Epirubicin—prostate cancer	3.38e-05	0.000175	CcSEcCtD
Pemetrexed—Nausea—Capecitabine—prostate cancer	3.37e-05	0.000175	CcSEcCtD
Pemetrexed—Dizziness—Prednisone—prostate cancer	3.34e-05	0.000173	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.33e-05	0.000173	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—prostate cancer	3.26e-05	0.000169	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Epirubicin—prostate cancer	3.23e-05	0.000167	CcSEcCtD
Pemetrexed—Dyspepsia—Doxorubicin—prostate cancer	3.21e-05	0.000167	CcSEcCtD
Pemetrexed—Vomiting—Prednisone—prostate cancer	3.21e-05	0.000166	CcSEcCtD
Pemetrexed—Rash—Prednisone—prostate cancer	3.18e-05	0.000165	CcSEcCtD
Pemetrexed—Dermatitis—Prednisone—prostate cancer	3.18e-05	0.000165	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—prostate cancer	3.17e-05	0.000165	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.15e-05	0.000164	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—prostate cancer	3.15e-05	0.000163	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—prostate cancer	3.14e-05	0.000163	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—prostate cancer	3.12e-05	0.000162	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—prostate cancer	3.12e-05	0.000162	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—prostate cancer	3.12e-05	0.000162	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—prostate cancer	3.12e-05	0.000162	CcSEcCtD
Pemetrexed—TYMS—Diflorasone—Prednisone—prostate cancer	3.11e-05	0.00735	CbGdCrCtD
Pemetrexed—Nausea—Prednisone—prostate cancer	3e-05	0.000156	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Doxorubicin—prostate cancer	2.99e-05	0.000155	CcSEcCtD
Pemetrexed—Hypersensitivity—Epirubicin—prostate cancer	2.91e-05	0.000151	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—prostate cancer	2.9e-05	0.000151	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—prostate cancer	2.89e-05	0.00015	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—prostate cancer	2.89e-05	0.00015	CcSEcCtD
Pemetrexed—Asthenia—Epirubicin—prostate cancer	2.83e-05	0.000147	CcSEcCtD
Pemetrexed—Pruritus—Epirubicin—prostate cancer	2.79e-05	0.000145	CcSEcCtD
Pemetrexed—TYMS—Budesonide—Prednisone—prostate cancer	2.73e-05	0.00644	CbGdCrCtD
Pemetrexed—Diarrhoea—Epirubicin—prostate cancer	2.7e-05	0.00014	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—prostate cancer	2.69e-05	0.00014	CcSEcCtD
Pemetrexed—Asthenia—Doxorubicin—prostate cancer	2.62e-05	0.000136	CcSEcCtD
Pemetrexed—TYMS—Danazol—Prednisone—prostate cancer	2.62e-05	0.00618	CbGdCrCtD
Pemetrexed—Dizziness—Epirubicin—prostate cancer	2.61e-05	0.000135	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—prostate cancer	2.58e-05	0.000134	CcSEcCtD
Pemetrexed—Vomiting—Epirubicin—prostate cancer	2.51e-05	0.00013	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—prostate cancer	2.5e-05	0.00013	CcSEcCtD
Pemetrexed—Rash—Epirubicin—prostate cancer	2.49e-05	0.000129	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—prostate cancer	2.49e-05	0.000129	CcSEcCtD
Pemetrexed—Dizziness—Doxorubicin—prostate cancer	2.42e-05	0.000125	CcSEcCtD
Pemetrexed—Nausea—Epirubicin—prostate cancer	2.34e-05	0.000122	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—prostate cancer	2.32e-05	0.00012	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—prostate cancer	2.3e-05	0.000119	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—prostate cancer	2.3e-05	0.000119	CcSEcCtD
Pemetrexed—Nausea—Doxorubicin—prostate cancer	2.17e-05	0.000113	CcSEcCtD
Pemetrexed—ATIC—Metabolism—CREBBP—prostate cancer	1.83e-05	0.000142	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP2E1—prostate cancer	1.83e-05	0.000141	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGF—prostate cancer	1.82e-05	0.000141	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—IRS1—prostate cancer	1.82e-05	0.000141	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PARP1—prostate cancer	1.82e-05	0.000141	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGFR4—prostate cancer	1.82e-05	0.000141	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	1.81e-05	0.00014	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NQO1—prostate cancer	1.81e-05	0.00014	CbGpPWpGaD
Pemetrexed—GART—Metabolism—EP300—prostate cancer	1.8e-05	0.000139	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HPGDS—prostate cancer	1.8e-05	0.000139	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARA—prostate cancer	1.8e-05	0.000139	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC22A1—prostate cancer	1.8e-05	0.000139	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CALCA—prostate cancer	1.8e-05	0.000139	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—ATM—prostate cancer	1.79e-05	0.000138	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP2C19—prostate cancer	1.79e-05	0.000138	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TH—prostate cancer	1.78e-05	0.000138	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—GSK3B—prostate cancer	1.77e-05	0.000137	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP3A4—prostate cancer	1.76e-05	0.000136	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SULT2A1—prostate cancer	1.75e-05	0.000135	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	1.75e-05	0.000135	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ACHE—prostate cancer	1.75e-05	0.000135	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTT1—prostate cancer	1.75e-05	0.000135	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—INS—prostate cancer	1.74e-05	0.000135	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CD—prostate cancer	1.74e-05	0.000134	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP1B1—prostate cancer	1.73e-05	0.000134	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP2A6—prostate cancer	1.73e-05	0.000134	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—MED12—prostate cancer	1.72e-05	0.000133	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HSPA1A—prostate cancer	1.72e-05	0.000133	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GNG5—prostate cancer	1.71e-05	0.000132	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CREBBP—prostate cancer	1.71e-05	0.000132	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CAV1—prostate cancer	1.69e-05	0.000131	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—prostate cancer	1.68e-05	0.00013	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKR1C3—prostate cancer	1.68e-05	0.00013	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GGT1—prostate cancer	1.68e-05	0.00013	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PRKACB—prostate cancer	1.67e-05	0.000129	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP17A1—prostate cancer	1.65e-05	0.000128	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NCOA1—prostate cancer	1.65e-05	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CASP9—prostate cancer	1.65e-05	0.000128	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NCOA3—prostate cancer	1.65e-05	0.000127	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—NOS3—prostate cancer	1.64e-05	0.000127	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP19A1—prostate cancer	1.63e-05	0.000126	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAP2K1—prostate cancer	1.63e-05	0.000126	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CD—prostate cancer	1.62e-05	0.000125	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PRKCQ—prostate cancer	1.6e-05	0.000124	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SERPINE1—prostate cancer	1.6e-05	0.000124	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NCOA2—prostate cancer	1.58e-05	0.000122	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HPGDS—prostate cancer	1.57e-05	0.000122	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—RXRA—prostate cancer	1.57e-05	0.000122	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP2C19—prostate cancer	1.56e-05	0.000121	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FGF2—prostate cancer	1.55e-05	0.00012	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1B—prostate cancer	1.55e-05	0.00012	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CG—prostate cancer	1.54e-05	0.000119	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—IL6—prostate cancer	1.54e-05	0.000119	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NOS3—prostate cancer	1.53e-05	0.000118	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTT1—prostate cancer	1.52e-05	0.000118	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ACHE—prostate cancer	1.52e-05	0.000118	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGF10—prostate cancer	1.52e-05	0.000118	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CB—prostate cancer	1.52e-05	0.000117	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MDM2—prostate cancer	1.52e-05	0.000117	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—COMT—prostate cancer	1.51e-05	0.000117	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP2A6—prostate cancer	1.51e-05	0.000117	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTP1—prostate cancer	1.51e-05	0.000117	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC5A5—prostate cancer	1.5e-05	0.000116	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—prostate cancer	1.5e-05	0.000116	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—JAK2—prostate cancer	1.48e-05	0.000115	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ITPR1—prostate cancer	1.48e-05	0.000115	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.48e-05	0.000114	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—prostate cancer	1.48e-05	0.000114	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP2E1—prostate cancer	1.47e-05	0.000114	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKR1C3—prostate cancer	1.47e-05	0.000113	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—INS—prostate cancer	1.46e-05	0.000113	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PRKACB—prostate cancer	1.46e-05	0.000113	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NQO1—prostate cancer	1.45e-05	0.000112	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MDM2—prostate cancer	1.45e-05	0.000112	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFBR2—prostate cancer	1.45e-05	0.000112	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP17A1—prostate cancer	1.44e-05	0.000112	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TH—prostate cancer	1.43e-05	0.000111	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CREBBP—prostate cancer	1.43e-05	0.00011	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ERBB2—prostate cancer	1.43e-05	0.00011	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—prostate cancer	1.43e-05	0.00011	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ITPR1—prostate cancer	1.42e-05	0.00011	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP3A4—prostate cancer	1.42e-05	0.000109	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CB—prostate cancer	1.41e-05	0.000109	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TYMS—prostate cancer	1.4e-05	0.000108	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—prostate cancer	1.4e-05	0.000108	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP1B1—prostate cancer	1.39e-05	0.000108	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTM1—prostate cancer	1.39e-05	0.000107	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1B—prostate cancer	1.38e-05	0.000107	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NCOA2—prostate cancer	1.38e-05	0.000106	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—LPL—prostate cancer	1.36e-05	0.000105	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EP300—prostate cancer	1.36e-05	0.000105	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CD—prostate cancer	1.36e-05	0.000105	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1B—prostate cancer	1.35e-05	0.000104	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GGT1—prostate cancer	1.35e-05	0.000104	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—prostate cancer	1.33e-05	0.000103	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NCOA1—prostate cancer	1.33e-05	0.000103	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1B—prostate cancer	1.32e-05	0.000102	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MDM2—prostate cancer	1.32e-05	0.000102	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—prostate cancer	1.32e-05	0.000102	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP1A1—prostate cancer	1.31e-05	0.000101	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC5A5—prostate cancer	1.31e-05	0.000101	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTEN—prostate cancer	1.31e-05	0.000101	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP19A1—prostate cancer	1.31e-05	0.000101	CbGpPWpGaD
Pemetrexed—DHFR—Disease—LPL—prostate cancer	1.3e-05	0.000101	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ERCC2—prostate cancer	1.3e-05	0.000101	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFRB—prostate cancer	1.29e-05	9.99e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—prostate cancer	1.29e-05	9.95e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP2E1—prostate cancer	1.28e-05	9.91e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—NOS3—prostate cancer	1.28e-05	9.89e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—prostate cancer	1.28e-05	9.87e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NQO1—prostate cancer	1.27e-05	9.8e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—RXRA—prostate cancer	1.26e-05	9.77e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—prostate cancer	1.25e-05	9.66e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERCC2—prostate cancer	1.25e-05	9.66e-05	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—EP300—prostate cancer	1.25e-05	9.66e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TH—prostate cancer	1.25e-05	9.65e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—prostate cancer	1.25e-05	9.63e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP3A4—prostate cancer	1.24e-05	9.55e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—MTHFR—prostate cancer	1.22e-05	9.46e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERBB3—prostate cancer	1.22e-05	9.45e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—prostate cancer	1.22e-05	9.44e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGFR2—prostate cancer	1.22e-05	9.43e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—prostate cancer	1.22e-05	9.42e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—COMT—prostate cancer	1.22e-05	9.41e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP1B1—prostate cancer	1.21e-05	9.39e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EP300—prostate cancer	1.21e-05	9.39e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTP1—prostate cancer	1.21e-05	9.36e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1B—prostate cancer	1.21e-05	9.33e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARA—prostate cancer	1.2e-05	9.28e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ITPR1—prostate cancer	1.19e-05	9.21e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EP300—prostate cancer	1.19e-05	9.16e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—prostate cancer	1.18e-05	9.15e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CB—prostate cancer	1.18e-05	9.13e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GGT1—prostate cancer	1.18e-05	9.09e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTHFR—prostate cancer	1.17e-05	9.08e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—prostate cancer	1.17e-05	9.05e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—prostate cancer	1.17e-05	9.05e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EP300—prostate cancer	1.16e-05	8.98e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NCOA1—prostate cancer	1.16e-05	8.96e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—prostate cancer	1.15e-05	8.9e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP19A1—prostate cancer	1.14e-05	8.83e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SRC—prostate cancer	1.13e-05	8.74e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CAV1—prostate cancer	1.13e-05	8.73e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMS—prostate cancer	1.13e-05	8.7e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HIF1A—prostate cancer	1.12e-05	8.66e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—prostate cancer	1.11e-05	8.61e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTM1—prostate cancer	1.11e-05	8.6e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—RXRA—prostate cancer	1.1e-05	8.52e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—LPL—prostate cancer	1.09e-05	8.45e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—STAT3—prostate cancer	1.09e-05	8.42e-05	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—prostate cancer	1.09e-05	8.42e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CAV1—prostate cancer	1.08e-05	8.37e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—COMT—prostate cancer	1.06e-05	8.21e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EP300—prostate cancer	1.06e-05	8.19e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—prostate cancer	1.06e-05	8.18e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTP1—prostate cancer	1.06e-05	8.17e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP1A1—prostate cancer	1.06e-05	8.16e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ERCC2—prostate cancer	1.05e-05	8.09e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ITPR1—prostate cancer	1.04e-05	8.04e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—prostate cancer	1.03e-05	7.98e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CG—prostate cancer	1.03e-05	7.95e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—prostate cancer	1.02e-05	7.89e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BAD—prostate cancer	1.02e-05	7.88e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—prostate cancer	1.01e-05	7.83e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFB1—prostate cancer	1.01e-05	7.81e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—prostate cancer	9.91e-06	7.66e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—APC—prostate cancer	9.87e-06	7.63e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—MTHFR—prostate cancer	9.84e-06	7.6e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IRS1—prostate cancer	9.76e-06	7.54e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGF—prostate cancer	9.76e-06	7.54e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—INS—prostate cancer	9.74e-06	7.53e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—EP300—prostate cancer	9.73e-06	7.52e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTM1—prostate cancer	9.71e-06	7.51e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARA—prostate cancer	9.65e-06	7.46e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CREBBP—prostate cancer	9.54e-06	7.37e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—LPL—prostate cancer	9.53e-06	7.37e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—GSK3B—prostate cancer	9.47e-06	7.32e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—prostate cancer	9.36e-06	7.23e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—INS—prostate cancer	9.34e-06	7.22e-05	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—prostate cancer	9.24e-06	7.14e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—prostate cancer	9.24e-06	7.14e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP1A1—prostate cancer	9.21e-06	7.12e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CREBBP—prostate cancer	9.15e-06	7.07e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ERCC2—prostate cancer	9.13e-06	7.06e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CAV1—prostate cancer	9.07e-06	7.01e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CD—prostate cancer	9.04e-06	6.99e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAP2K1—prostate cancer	8.73e-06	6.75e-05	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—prostate cancer	8.69e-06	6.72e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CD—prostate cancer	8.68e-06	6.71e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—prostate cancer	8.6e-06	6.65e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—MTHFR—prostate cancer	8.58e-06	6.63e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SERPINE1—prostate cancer	8.58e-06	6.63e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NOS3—prostate cancer	8.54e-06	6.6e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARA—prostate cancer	8.42e-06	6.51e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGF2—prostate cancer	8.31e-06	6.42e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CG—prostate cancer	8.27e-06	6.39e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NOS3—prostate cancer	8.19e-06	6.33e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—JAK2—prostate cancer	7.96e-06	6.15e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CAV1—prostate cancer	7.92e-06	6.12e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CB—prostate cancer	7.88e-06	6.09e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—INS—prostate cancer	7.82e-06	6.05e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—prostate cancer	7.81e-06	6.04e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MDM2—prostate cancer	7.77e-06	6.01e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CREBBP—prostate cancer	7.66e-06	5.92e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERBB2—prostate cancer	7.66e-06	5.92e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—IL6—prostate cancer	7.61e-06	5.88e-05	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—prostate cancer	7.59e-06	5.86e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CB—prostate cancer	7.56e-06	5.85e-05	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—prostate cancer	7.55e-06	5.84e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—prostate cancer	7.49e-06	5.79e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CD—prostate cancer	7.27e-06	5.62e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CG—prostate cancer	7.21e-06	5.57e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—prostate cancer	7.2e-06	5.57e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1B—prostate cancer	7.1e-06	5.49e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—prostate cancer	7.02e-06	5.43e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NOS3—prostate cancer	6.86e-06	5.3e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—INS—prostate cancer	6.83e-06	5.28e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—prostate cancer	6.81e-06	5.26e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—prostate cancer	6.7e-06	5.18e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CREBBP—prostate cancer	6.69e-06	5.17e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—prostate cancer	6.55e-06	5.06e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—prostate cancer	6.53e-06	5.05e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—EP300—prostate cancer	6.49e-06	5.02e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CD—prostate cancer	6.34e-06	4.9e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CB—prostate cancer	6.33e-06	4.9e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—prostate cancer	6.28e-06	4.85e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EP300—prostate cancer	6.23e-06	4.82e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SRC—prostate cancer	6.06e-06	4.68e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NOS3—prostate cancer	5.99e-06	4.63e-05	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—prostate cancer	5.88e-06	4.55e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—STAT3—prostate cancer	5.84e-06	4.52e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CB—prostate cancer	5.53e-06	4.27e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—prostate cancer	5.48e-06	4.23e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—prostate cancer	5.47e-06	4.23e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—prostate cancer	5.43e-06	4.2e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFB1—prostate cancer	5.42e-06	4.19e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—prostate cancer	5.31e-06	4.11e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—EP300—prostate cancer	5.22e-06	4.03e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—prostate cancer	5.02e-06	3.88e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—prostate cancer	4.8e-06	3.71e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—prostate cancer	4.78e-06	3.69e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—prostate cancer	4.61e-06	3.56e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—EP300—prostate cancer	4.55e-06	3.52e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IL6—prostate cancer	4.08e-06	3.16e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—prostate cancer	3.92e-06	3.03e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—prostate cancer	3.86e-06	2.98e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—prostate cancer	3.77e-06	2.91e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—prostate cancer	3.37e-06	2.6e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—prostate cancer	3.15e-06	2.44e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—prostate cancer	2.75e-06	2.13e-05	CbGpPWpGaD
